13: Regulatory Issues and Medications for Opioid Use Disorder (MOUD)
At the conclusion of this activity participants should be able to describe the historical evolution and current state of the policies regulating office based prescribing of medications for opioid use disorder, and distinguish these from the federal regulations applicable to opioid treatment programs (OTPs). Participants will also be able to which identify which prescribing clinicians are eligible for the DATA-2000 waiver, the applicable waiver limits including the relevant practice settings impacting waiver limits, and the specific medications for opioid use disorder and clinic settings where the DATA-2000 does not apply. Participants will also be able to explain applicable privacy regulations and the regulations governing managing medications for opioid use disorder via telehealth.
20: Treating Pregnant People for Opioid Use Disorder: Clinical Challenges
Opioid use disorder (OUD) among women and people who become pregnant is increasing in prevalence in clinical settings. The standard of care is to provide buprenorphine or methadone as a part of a complete treatment approach during pregnancy and beyond the postpartum period. This module reviews the historical and current context of opioid use among women and birthing people during pregnancy. It compares pharmacological treatment options for women and people who become pregnant with an OUD and also discusses the issues with detoxification or medically assisted withdrawal from opioids during pregnancy. Issues related to the treatment of OUD during pregnancy and in the postpartum period for the birthing person, fetus and child will also be discussed (e.g., induction, dosing, pain management, neonatal withdrawal and how to reduce its severity).
